Wenhao Hu

Florida State University — United States

Chemistry · Physical Sciences

60h-index14.6kcitations985works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cyclopropane Reaction Mechanisms(340), Catalytic C–H Functionalization Methods(193), Asymmetric Synthesis and Catalysis(139), HER2/EGFR in Cancer Research(127), Synthetic Organic Chemistry Methods(108)

Publications985 total

Nitric oxide-releasing porphyrinic metal-organic frameworks as a promising antimicrobial material against foodborne pathogens
Innovative Food Science & Emerging Technologies·2025
Rhodium( <scp>ii</scp> )-incorporated metal–organic framework catalyst combined with flow chemistry for efficient carbene-mediated three-component reactions
Organic & Biomolecular Chemistry·2025
Figure S1-S19 from Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
2025Open Access
Supplementary note from Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
2025Open Access
Table S1-S7 from Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer
2025Open Access
Correction to “Multicomponent Reaction-Enabled Semisynthesis of Taxanes Yields an Analogue with Reduced Chemotherapy-Induced Neuropathy”
JACS Au·2025Open Access
Predictive value of the VBQ score for internal fixation failure after PLIF and determinants of its cutoff value
Spine Research·2025Open Access
Supplementary Fig.S1 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
2025Open Access
Supplementary Figure 5 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
2025Open Access
Supplementary Fig.S5 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
2025Open Access
Supplementary Figure 13 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
2025Open Access
Supplementary Figure 2 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
2025Open Access
Supplementary Figure 10 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
2025Open Access
Supplementary Figure 6 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
2025Open Access
Supplementary Figure 9 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
2025Open Access
Supplementary Figure 3 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
2025Open Access
Supplementary Figure 11 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
2025Open Access
Supplementary Figure 4 from AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
2025Open Access
Supplementary Fig.S7 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
2025Open Access
Supplementary Fig.S2 from MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
2025Open Access
page 1 of 50Next →

Frequent Co-authors

Michael P. Doyle(10), Xinfang Xu(9), Xin Guo(5), Dan Zhang(5), Haoxi Huang(4), Liqin Jiang(4), Aiqiao Mi(4), Dong Xing(4), Yu Qian(4), Zhenghui Kang(3), Yuanxiang Wang(3), Jing Zhou(2), Liping Yang(2), Liu‐Zhu Gong(2), Huang Qiu(2), Jun Jiang(2), Hua‐Dong Xu(2), Fengping Lv(2), Albert S. C. Chan(2), Yaozhong Jiang(2)